lifestyle.celebhomes.net
Home
Sample Page
Author:
Erasca, Inc.
Erasca Reports First Quarter 2026 Business Updates and Financial Results
May 11, 2026
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
May 11, 2026
Erasca to Present at the Bank of America Securities Health Care Conference
May 6, 2026
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
April 27, 2026
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
April 27, 2026
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
March 12, 2026
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
March 10, 2026
Erasca to Present at Upcoming Conferences in February
February 6, 2026
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 23, 2026
Erasca Announces Pricing of Upsized Public Offering of Common Stock
January 22, 2026
1
2
Next Page
→